Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.
|6||Active, not recruiting||
CT Antigen TCR-Engineered T Cells for Myeloma
Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder
Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma
† Study has passed its completion date and status has not been verified in more than two years.